Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic's latest technology, the MiniMedTM 780G system with Meal DetectionTM technology, is helping individuals like Jodie Snavely manage their type 1 diabetes effectively. The system automatically adjusts and corrects sugar levels every five minutes, preventing blood sugar spikes. This advancement in diabetes management technology provides peace of mind to users by maintaining stable blood sugar levels, reducing the need for constant monitoring and worry.
Medtronic plc (NYSE:MDT) will announce its financial results for the fourth quarter and full fiscal year 2024 on Thursday, May 23, 2024. The company will release summary financial information for the period ending on Friday, April 26, 2024. The results will be discussed in a video webcast at 7:00 a.m. CDT on the same day, with a replay and transcript available within 24 hours. Medtronic plans to report fiscal year 2025 results on various dates later in the year.
In a recent press release by Medtronic, Chief Scientific and Medical Officer Laura Mauri discusses the intersection of healthcare and technology in achieving longevity. While many Americans aspire to live past 90, the survey reveals a preference for a shorter, healthier life. Despite belief in healthcare technology, engagement in preventative measures remains low. Medtronic aims to bridge this gap by providing innovative solutions that enhance patient outcomes and experiences. By sharing four actions under the acronym T.E.C.H., individuals are encouraged to take charge of their health and well-being.
Medtronic's groundbreaking SMART clinical trial focusing on women with aortic stenosis marks a pivotal moment in women's health. The study compared Medtronic's Evolut transcatheter aortic heart valve system with Edwards Sapien, revealing superior performance of the Evolut system. Female-specific data from the trial sheds light on gender inequities in heart health care, emphasizing the need to address underrepresentation of women in clinical trials.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.